Nanyang Biologics Pte. Ltd., together with its subsidiaries (collectively, the "Company", "we" or "NYB"), offers a comprehensive drug discovery platform that integrates the wisdom of traditional medicine with state-of-the-art technologies. Patented Flagship NB-A002 is a First-in-class DNA...
Hence then, the article about ai drug discovery pioneer nanyang biologics pte ltd enters into business combination agreement with rf acquisition corp ii in us 1 5b transaction to pursue public listing was published today ( ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.
Read More Details
Finally We wish PressBee provided you with enough information of ( AI Drug Discovery Pioneer, Nanyang Biologics Pte. Ltd., Enters into Business Combination Agreement with RF Acquisition Corp II in US$1.5B Transaction to Pursue Public Listing )
Also on site :
- Quantum Communication Fieldlab Rotterdam moves quantum-secure communication from pilot to operational use
- Saudi Aramco Eyes $7 Billion Sulfur Asset Sale as Demand Soars
- I’m a 30-year-old charity founder – here’s why my generation should switch Netflix for an ‘impact subscription’